| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 526,407 | PSNL, MRNA, KYMR, AKTIS ONCOLOGY INC | 13F-HR | 8/7/2026 | 000031015826000210 |
| Q1 2026 | 14 | 349,437 | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC | 13F-HR | 5/13/2026 | 000031015826000141 |
| Q4 2025 | 12 | 276,276 | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC | 13F-HR | 2/17/2026 | 000031015826000055 |
| Q3 2025 | 13 | 228,030 | PSNL, MRNA, KYMR, ALEC | 13F-HR | 11/12/2025 | 000031015825000063 |
| Q2 2025 | 13 | 215,600 | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC | 13F-HR | 8/13/2025 | 000169130425000005 |
| Q1 2025 | 12 | 164,284 | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC | 13F-HR | 5/14/2025 | 000006497825000005 |
| Q4 2024 | 13 | 258,037 | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC | 13F-HR | 2/14/2025 | 000089534525000055 |
Investors who own more than 5% of a class must file a Schedule 13D or 13G.
2 securities where the latest filing since 12/18/2024 is a 13G, the newest filed 2/3/2025. View all